ID   PGDH_HUMAN              Reviewed;         266 AA.
AC   P15428; B4DTA4; B4DU74; B4DV57; D3DP43; E7EV11; O00749; Q06F08;
AC   Q12998;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   10-MAY-2017, entry version 179.
DE   RecName: Full=15-hydroxyprostaglandin dehydrogenase [NAD(+)];
DE            Short=15-PGDH;
DE            EC=1.1.1.141;
DE   AltName: Full=Prostaglandin dehydrogenase 1;
DE   AltName: Full=Short chain dehydrogenase/reductase family 36C member 1;
GN   Name=HPGD; Synonyms=PGDH1, SDR36C1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   PROTEIN SEQUENCE.
RC   TISSUE=Placenta;
RX   PubMed=2337593; DOI=10.1021/bi00455a021;
RA   Krook M., Marekov L., Joernvall H.;
RT   "Purification and structural characterization of placental NAD(+)-
RT   linked 15-hydroxyprostaglandin dehydrogenase. The primary structure
RT   reveals the enzyme to belong to the short-chain alcohol dehydrogenase
RT   family.";
RL   Biochemistry 29:738-743(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=1697582;
RA   Ensor C.M., Yang J.Y., Okita R.T., Tai H.-H.;
RT   "Cloning and sequence analysis of the cDNA for human placental NAD(+)-
RT   dependent 15-hydroxyprostaglandin dehydrogenase.";
RL   J. Biol. Chem. 265:14888-14891(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Leukemia;
RX   PubMed=7557451; DOI=10.1016/0378-1119(95)00319-2;
RA   Pichaud F., Frendo J.L., Delage-Mourroux R., de Vernejoul M.C.,
RA   Moukhtar M.S., Jullienne A.;
RT   "Sequence of a novel mRNA coding for a C-terminal-truncated form of
RT   human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase.";
RL   Gene 162:319-322(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   PubMed=9099873; DOI=10.1016/S0378-1119(96)00800-1;
RA   Delage-Mourroux R., Pichaud F., Frendo J.L., Pidoux E., Guliana J.M.,
RA   Moukhtar M.S., Jullienne A.;
RT   "Cloning and sequencing of a new 15-hydroxyprostaglandin dehydrogenase
RT   related mRNA.";
RL   Gene 188:143-148(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 5).
RC   TISSUE=Colon, Placenta, and Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   MUTAGENESIS OF TYR-151.
RX   PubMed=2025296; DOI=10.1016/S0006-291X(05)80262-1;
RA   Ensor C.M., Tai H.-H.;
RT   "Site-directed mutagenesis of the conserved tyrosine 151 of human
RT   placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase
RT   yields a catalytically inactive enzyme.";
RL   Biochem. Biophys. Res. Commun. 176:840-845(1991).
RN   [11]
RP   FUNCTION.
RX   PubMed=10837478; DOI=10.1074/jbc.M002863200;
RA   Clish C.B., Levy B.D., Chiang N., Tai H.-H., Serhan C.N.;
RT   "Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role
RT   for 15-onoprostaglandin 13-reductase/leukotriene B4 12-
RT   hydroxydehydrogenase in inflammation.";
RL   J. Biol. Chem. 275:25372-25380(2000).
RN   [12]
RP   INDUCTION.
RX   PubMed=12788907; DOI=10.1210/jc.2002-021710;
RA   Patel F.A., Funder J.W., Challis J.R.G.;
RT   "Mechanism of cortisol/progesterone antagonism in the regulation of
RT   15-hydroxyprostaglandin dehydrogenase activity and messenger
RT   ribonucleic acid levels in human chorion and placental trophoblast
RT   cells at term.";
RL   J. Clin. Endocrinol. Metab. 88:2922-2933(2003).
RN   [13]
RP   FUNCTION, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15574495; DOI=10.1073/pnas.0406142101;
RA   Yan M., Rerko R.M., Platzer P., Dawson D., Willis J., Tong M.,
RA   Lawrence E., Lutterbaugh J., Lu S., Willson J.K.V., Luo G.,
RA   Hensold J., Tai H.-H., Wilson K., Markowitz S.D.;
RT   "15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist,
RT   is a TGF-beta-induced suppressor of human gastrointestinal cancers.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:17468-17473(2004).
RN   [14]
RP   FUNCTION, MUTAGENESIS OF GLN-148, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   3D-STRUCTURE MODELING.
RX   PubMed=16828555; DOI=10.1016/j.bmc.2006.06.030;
RA   Cho H., Huang L., Hamza A., Gao D., Zhan C.-G., Tai H.-H.;
RT   "Role of glutamine 148 of human 15-hydroxyprostaglandin dehydrogenase
RT   in catalytic oxidation of prostaglandin E2.";
RL   Bioorg. Med. Chem. 14:6486-6491(2006).
RN   [15]
RP   3D-STRUCTURE MODELING.
RX   PubMed=8482380; DOI=10.1016/0014-5793(93)81554-D;
RA   Krook M., Ghosh D., Duax W.L., Joernvall H.;
RT   "Three-dimensional model of NAD(+)-dependent 15-hydroxyprostaglandin
RT   dehydrogenase and relationships to the NADP(+)-dependent enzyme
RT   (carbonyl reductase).";
RL   FEBS Lett. 322:139-142(1993).
RN   [16]
RP   INVOLVEMENT IN PHOAR1, VARIANT COA PRO-140, AND CHARACTERIZATION OF
RP   VARIANT COA PRO-140.
RX   PubMed=18500342; DOI=10.1038/ng.153;
RA   Uppal S., Diggle C.P., Carr I.M., Fishwick C.W.G., Ahmed M.,
RA   Ibrahim G.H., Helliwell P.S., Latos-Bielenska A., Phillips S.E.V.,
RA   Markham A.F., Bennett C.P., Bonthron D.T.;
RT   "Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary
RT   hypertrophic osteoarthropathy.";
RL   Nat. Genet. 40:789-793(2008).
RN   [17]
RP   ERRATUM.
RA   Uppal S., Diggle C.P., Carr I.M., Fishwick C.W.G., Ahmed M.,
RA   Ibrahim G.H., Helliwell P.S., Latos-Bielenska A., Phillips S.E.V.,
RA   Markham A.F., Bennett C.P., Bonthron D.T.;
RL   Nat. Genet. 40:927-927(2008).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 3-256 IN COMPLEX WITH NAD.
RX   PubMed=21072165; DOI=10.1371/journal.pone.0013719;
RA   Niesen F.H., Schultz L., Jadhav A., Bhatia C., Guo K., Maloney D.J.,
RA   Pilka E.S., Wang M., Oppermann U., Heightman T.D., Simeonov A.;
RT   "High-affinity inhibitors of human NAD-dependent 15-
RT   hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and
RT   structure-activity relationships.";
RL   PLoS ONE 5:E13719-E13719(2010).
RN   [19]
RP   VARIANT ICNC PRO-193.
RX   PubMed=18805827; DOI=10.1136/jmg.2008.061234;
RA   Tariq M., Azeem Z., Ali G., Chishti M.S., Ahmad W.;
RT   "Mutation in the HPGD gene encoding NAD+ dependent 15-
RT   hydroxyprostaglandin dehydrogenase underlies isolated congenital nail
RT   clubbing (ICNC).";
RL   J. Med. Genet. 46:14-20(2009).
CC   -!- FUNCTION: Prostaglandin inactivation. Contributes to the
CC       regulation of events that are under the control of prostaglandin
CC       levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4
CC       to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon
CC       cancer cells. {ECO:0000269|PubMed:10837478,
CC       ECO:0000269|PubMed:15574495, ECO:0000269|PubMed:16828555}.
CC   -!- CATALYTIC ACTIVITY: (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-
CC       5,13-dienoate + NAD(+) = (5Z,13E)-11-alpha-hydroxy-9,15-
CC       dioxoprost-5,13-dienoate + NADH.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.4 uM for prostaglandin E2 {ECO:0000269|PubMed:16828555};
CC         KM=38 uM for NAD {ECO:0000269|PubMed:16828555};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:21072165}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P15428-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15428-2; Sequence=VSP_043032;
CC       Name=3;
CC         IsoId=P15428-3; Sequence=VSP_045106;
CC       Name=4;
CC         IsoId=P15428-4; Sequence=VSP_045107, VSP_045108;
CC       Name=5;
CC         IsoId=P15428-5; Sequence=VSP_045579;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in colon epithelium (at protein
CC       level). {ECO:0000269|PubMed:15574495}.
CC   -!- INDUCTION: Down-regulated by cortisol, dexamethasone and
CC       betamethasone. Down-regulated in colon cancer. Up-regulated by
CC       TGFB1. {ECO:0000269|PubMed:12788907, ECO:0000269|PubMed:15574495}.
CC   -!- DISEASE: Hypertrophic osteoarthropathy, primary, autosomal
CC       recessive, 1 (PHOAR1) [MIM:259100]: A disease characterized by
CC       digital clubbing, periostosis, acroosteolysis, painful joint
CC       enlargement, and variable features of pachydermia that include
CC       thickened facial skin and a thickened scalp. Other developmental
CC       anomalies include delayed closure of the cranial sutures and
CC       congenital heart disease. {ECO:0000269|PubMed:18500342}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Cranioosteoarthropathy (COA) [MIM:259100]: A form of
CC       osteoarthropathy characterized by swelling of the joints, digital
CC       clubbing, hyperhidrosis, delayed closure of the fontanels,
CC       periostosis, and variable patent ductus arteriosus. Pachydermia is
CC       not a prominent feature. {ECO:0000269|PubMed:18500342}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Isolated congenital nail clubbing (ICNC) [MIM:119900]: A
CC       rare genodermatosis characterized by enlargement of the nail plate
CC       and terminal segments of the fingers and toes, resulting from
CC       proliferation of the connective tissues between the nail matrix
CC       and the distal phalanx. It is usually symmetrical and bilateral
CC       (in some cases unilateral). In nail clubbing usually the distal
CC       end of the nail matrix is relatively high compared to the proximal
CC       end, while the nail plate is complete but its dimensions and
CC       diameter more or less vary in comparison to normal. There may be
CC       different fingers and toes involved to varying degrees. Some
CC       fingers or toes are spared, but the thumbs are almost always
CC       involved. {ECO:0000269|PubMed:18805827}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases
CC       (SDR) family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/hpgd/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L76465; AAA89175.1; -; mRNA.
DR   EMBL; J05594; AAA89174.1; -; mRNA.
DR   EMBL; X82460; CAA57843.1; -; mRNA.
DR   EMBL; U63296; AAB53034.1; -; mRNA.
DR   EMBL; AK296642; BAH12408.1; -; mRNA.
DR   EMBL; AK300125; BAG61916.1; -; mRNA.
DR   EMBL; AK300524; BAG62236.1; -; mRNA.
DR   EMBL; AK300940; BAG62569.1; -; mRNA.
DR   EMBL; AK314624; BAG37190.1; -; mRNA.
DR   EMBL; DQ903072; ABI75347.1; -; Genomic_DNA.
DR   EMBL; AC096751; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471056; EAX04734.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04735.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04736.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04737.1; -; Genomic_DNA.
DR   EMBL; BC018986; AAH18986.1; -; mRNA.
DR   CCDS; CCDS3821.1; -. [P15428-1]
DR   CCDS; CCDS54821.1; -. [P15428-2]
DR   CCDS; CCDS58933.1; -. [P15428-3]
DR   CCDS; CCDS58934.1; -. [P15428-5]
DR   CCDS; CCDS58935.1; -. [P15428-4]
DR   PIR; A35802; A35802.
DR   RefSeq; NP_000851.2; NM_000860.5. [P15428-1]
DR   RefSeq; NP_001139288.1; NM_001145816.2. [P15428-2]
DR   RefSeq; NP_001243230.1; NM_001256301.1. [P15428-3]
DR   RefSeq; NP_001243234.1; NM_001256305.1. [P15428-4]
DR   RefSeq; NP_001243235.1; NM_001256306.1. [P15428-5]
DR   RefSeq; NP_001243236.1; NM_001256307.1. [P15428-3]
DR   UniGene; Hs.596913; -.
DR   PDB; 2GDZ; X-ray; 1.65 A; A=3-256.
DR   PDBsum; 2GDZ; -.
DR   ProteinModelPortal; P15428; -.
DR   SMR; P15428; -.
DR   BioGrid; 109485; 1.
DR   STRING; 9606.ENSP00000296522; -.
DR   BindingDB; P15428; -.
DR   ChEMBL; CHEMBL1293255; -.
DR   DrugBank; DB00157; NADH.
DR   GuidetoPHARMACOLOGY; 1384; -.
DR   SwissLipids; SLP:000000732; -.
DR   iPTMnet; P15428; -.
DR   PhosphoSitePlus; P15428; -.
DR   BioMuta; HPGD; -.
DR   DMDM; 129889; -.
DR   SWISS-2DPAGE; P15428; -.
DR   EPD; P15428; -.
DR   MaxQB; P15428; -.
DR   PaxDb; P15428; -.
DR   PeptideAtlas; P15428; -.
DR   PRIDE; P15428; -.
DR   Ensembl; ENST00000296521; ENSP00000296521; ENSG00000164120. [P15428-2]
DR   Ensembl; ENST00000296522; ENSP00000296522; ENSG00000164120. [P15428-1]
DR   Ensembl; ENST00000422112; ENSP00000398720; ENSG00000164120. [P15428-5]
DR   Ensembl; ENST00000510901; ENSP00000422418; ENSG00000164120. [P15428-3]
DR   Ensembl; ENST00000541923; ENSP00000438017; ENSG00000164120. [P15428-3]
DR   Ensembl; ENST00000542498; ENSP00000443644; ENSG00000164120. [P15428-4]
DR   GeneID; 3248; -.
DR   KEGG; hsa:3248; -.
DR   UCSC; uc003itu.3; human. [P15428-1]
DR   CTD; 3248; -.
DR   DisGeNET; 3248; -.
DR   GeneCards; HPGD; -.
DR   HGNC; HGNC:5154; HPGD.
DR   HPA; HPA004919; -.
DR   HPA; HPA005679; -.
DR   MalaCards; HPGD; -.
DR   MIM; 119900; phenotype.
DR   MIM; 259100; phenotype.
DR   MIM; 601688; gene.
DR   neXtProt; NX_P15428; -.
DR   OpenTargets; ENSG00000164120; -.
DR   Orphanet; 1525; Cranio-osteoarthropathy.
DR   Orphanet; 217059; Isolated congenital digital clubbing.
DR   Orphanet; 2796; Pachydermoperiostosis.
DR   PharmGKB; PA29424; -.
DR   eggNOG; KOG4169; Eukaryota.
DR   eggNOG; COG1028; LUCA.
DR   GeneTree; ENSGT00760000118868; -.
DR   HOGENOM; HOG000070121; -.
DR   HOVERGEN; HBG107379; -.
DR   InParanoid; P15428; -.
DR   KO; K00069; -.
DR   OMA; QRTLFIQ; -.
DR   OrthoDB; EOG091G0OC9; -.
DR   PhylomeDB; P15428; -.
DR   TreeFam; TF324093; -.
DR   BRENDA; 1.1.1.141; 2681.
DR   Reactome; R-HSA-2142700; Synthesis of Lipoxins (LX).
DR   Reactome; R-HSA-2162123; Synthesis of Prostaglandins (PG) and Thromboxanes (TX).
DR   SABIO-RK; P15428; -.
DR   ChiTaRS; HPGD; human.
DR   EvolutionaryTrace; P15428; -.
DR   GeneWiki; HPGD; -.
DR   GenomeRNAi; 3248; -.
DR   PRO; PR:P15428; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000164120; -.
DR   CleanEx; HS_HPGD; -.
DR   ExpressionAtlas; P15428; baseline and differential.
DR   Genevisible; P15428; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0016404; F:15-hydroxyprostaglandin dehydrogenase (NAD+) activity; IDA:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; IDA:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IDA:UniProtKB.
DR   GO; GO:0070403; F:NAD+ binding; IDA:UniProtKB.
DR   GO; GO:0004957; F:prostaglandin E receptor activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; TAS:UniProtKB.
DR   GO; GO:0097070; P:ductus arteriosus closure; ISS:UniProtKB.
DR   GO; GO:0007565; P:female pregnancy; IDA:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:2001300; P:lipoxin metabolic process; TAS:Reactome.
DR   GO; GO:0019372; P:lipoxygenase pathway; TAS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0030728; P:ovulation; ISS:UniProtKB.
DR   GO; GO:0007567; P:parturition; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0006693; P:prostaglandin metabolic process; IDA:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0070493; P:thrombin-activated receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR020904; Sc_DH/Rdtase_CS.
DR   InterPro; IPR002347; SDR_fam.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   PRINTS; PR00080; SDRFAMILY.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00061; ADH_SHORT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Fatty acid metabolism;
KW   Lipid metabolism; NAD; Oxidoreductase; Polymorphism;
KW   Prostaglandin metabolism; Reference proteome; Tumor suppressor.
FT   CHAIN         1    266       15-hydroxyprostaglandin dehydrogenase
FT                                [NAD(+)].
FT                                /FTId=PRO_0000054744.
FT   NP_BIND      12     20       NAD. {ECO:0000269|PubMed:21072165}.
FT   NP_BIND      36     37       NAD. {ECO:0000269|PubMed:21072165}.
FT   NP_BIND      63     65       NAD. {ECO:0000269|PubMed:21072165}.
FT   NP_BIND     151    155       NAD. {ECO:0000269|PubMed:21072165}.
FT   NP_BIND     186    188       NAD. {ECO:0000269|PubMed:21072165}.
FT   ACT_SITE    151    151       Proton acceptor.
FT   BINDING      91     91       NAD; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:21072165}.
FT   BINDING     138    138       Substrate. {ECO:0000305}.
FT   BINDING     148    148       Substrate. {ECO:0000305}.
FT   VAR_SEQ       1    121       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045106.
FT   VAR_SEQ      73    140       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045579.
FT   VAR_SEQ     140    143       AGLM -> AAHH (in isoform 4).
FT                                {ECO:0000303|PubMed:9099873}.
FT                                /FTId=VSP_045107.
FT   VAR_SEQ     144    266       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:9099873}.
FT                                /FTId=VSP_045108.
FT   VAR_SEQ     167    266       LAANLMNSGVRLNAICPGFVNTAILESIEKEENMGQYIEYK
FT                                DHIKDMIKYYGILDPPLIANGLITLIEDDALNGAIMKITTS
FT                                KGIHFQDYDTTPFQAKTQ -> PTIDCQWIDNTH (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:7557451}.
FT                                /FTId=VSP_043032.
FT   VARIANT     140    140       A -> P (in COA; inactive;
FT                                dbSNP:rs121434480).
FT                                {ECO:0000269|PubMed:18500342}.
FT                                /FTId=VAR_046209.
FT   VARIANT     193    193       S -> P (in ICNC; dbSNP:rs121434481).
FT                                {ECO:0000269|PubMed:18805827}.
FT                                /FTId=VAR_060792.
FT   VARIANT     217    217       Y -> C (in dbSNP:rs140209262).
FT                                /FTId=VAR_006972.
FT   MUTAGEN     148    148       Q->A: Loss of activity.
FT                                {ECO:0000269|PubMed:16828555}.
FT   MUTAGEN     148    148       Q->E,H,N: Reduced affinity for NAD and
FT                                prostaglandin E2.
FT                                {ECO:0000269|PubMed:16828555}.
FT   MUTAGEN     151    151       Y->A: Loss of activity.
FT                                {ECO:0000269|PubMed:2025296}.
FT   CONFLICT     50     50       D -> H (in Ref. 2; AAA89175/AAA89174).
FT                                {ECO:0000305}.
FT   CONFLICT     97     97       E -> K (in Ref. 3; CAA57843).
FT                                {ECO:0000305}.
FT   CONFLICT    219    219       I -> V (in Ref. 5; BAG61916).
FT                                {ECO:0000305}.
FT   STRAND        7     11       {ECO:0000244|PDB:2GDZ}.
FT   TURN         12     14       {ECO:0000244|PDB:2GDZ}.
FT   HELIX        16     27       {ECO:0000244|PDB:2GDZ}.
FT   STRAND       31     37       {ECO:0000244|PDB:2GDZ}.
FT   HELIX        39     49       {ECO:0000244|PDB:2GDZ}.
FT   TURN         50     52       {ECO:0000244|PDB:2GDZ}.
FT   HELIX        55     57       {ECO:0000244|PDB:2GDZ}.
FT   STRAND       58     62       {ECO:0000244|PDB:2GDZ}.
FT   HELIX        68     82       {ECO:0000244|PDB:2GDZ}.
FT   STRAND       87     90       {ECO:0000244|PDB:2GDZ}.
FT   STRAND       97     99       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       100    107       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       109    122       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       124    126       {ECO:0000244|PDB:2GDZ}.
FT   STRAND      131    136       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       139    141       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       149    172       {ECO:0000244|PDB:2GDZ}.
FT   STRAND      176    184       {ECO:0000244|PDB:2GDZ}.
FT   STRAND      186    188       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       189    192       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       193    195       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       197    200       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       201    206       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       207    217       {ECO:0000244|PDB:2GDZ}.
FT   HELIX       222    234       {ECO:0000244|PDB:2GDZ}.
FT   STRAND      242    246       {ECO:0000244|PDB:2GDZ}.
FT   TURN        247    249       {ECO:0000244|PDB:2GDZ}.
FT   STRAND      250    253       {ECO:0000244|PDB:2GDZ}.
SQ   SEQUENCE   266 AA;  28977 MW;  B860D2DE80E49514 CRC64;
     MHVNGKVALV TGAAQGIGRA FAEALLLKGA KVALVDWNLE AGVQCKAALD EQFEPQKTLF
     IQCDVADQQQ LRDTFRKVVD HFGRLDILVN NAGVNNEKNW EKTLQINLVS VISGTYLGLD
     YMSKQNGGEG GIIINMSSLA GLMPVAQQPV YCASKHGIVG FTRSAALAAN LMNSGVRLNA
     ICPGFVNTAI LESIEKEENM GQYIEYKDHI KDMIKYYGIL DPPLIANGLI TLIEDDALNG
     AIMKITTSKG IHFQDYDTTP FQAKTQ
//
